0001178913-23-002227.txt : 20230616 0001178913-23-002227.hdr.sgml : 20230616 20230616160305 ACCESSION NUMBER: 0001178913-23-002227 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230614 FILED AS OF DATE: 20230616 DATE AS OF CHANGE: 20230616 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fatal Sigal CENTRAL INDEX KEY: 0001850994 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38807 FILM NUMBER: 231020894 MAIL ADDRESS: STREET 1: 16 KANFEY NESHARIM ST. CITY: RAMAT GAN STATE: L3 ZIP: 5235716 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Chemomab Therapeutics Ltd. CENTRAL INDEX KEY: 0001534248 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813676773 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: KIRYAT ATIDIM, BUILDING 7 CITY: TEL AVIV STATE: L3 ZIP: 6158002 BUSINESS PHONE: 972-77-331-0156 MAIL ADDRESS: STREET 1: KIRYAT ATIDIM, BUILDING 7 CITY: TEL AVIV STATE: L3 ZIP: 6158002 FORMER COMPANY: FORMER CONFORMED NAME: Anchiano Therapeutics Ltd. DATE OF NAME CHANGE: 20180906 FORMER COMPANY: FORMER CONFORMED NAME: BioCancell Ltd. DATE OF NAME CHANGE: 20111104 4 1 ownership.xml X0407 4 2023-06-14 0 0001534248 Chemomab Therapeutics Ltd. CMMB 0001850994 Fatal Sigal 16 KANFEY NESHARIM ST. RAMAT GAN L3 5235716 ISRAEL 0 1 0 0 Chief Financial Officer 0 American Depositary Shares 5209 D Option to Purchase American Depositary Shares 1.70 2023-06-14 4 A 0 102860 0 A 2033-06-14 American Depositary Shares 102860 167860 D Option to Purchase American Depositary Shares 2.11 2022-11-08 4 A 0 29400 0 A 2032-11-08 American Depositary Shares 29400 65000 D Option to Purchase American Depositary Shares 9.83 2021-11-11 4 A 0 35600 0 A 2031-11-11 American Depositary Shares 35600 35600 D Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this form 4 for informational purposes only. Options granted under the Company's 2017 Equity-Based Incentive Plan (the "Plan") on June 14, 2023; 25% of the options vest and become exercisable following 12 months from the grant thereof and an additional 6.25% vests at the end of each calendar quarter thereafter such that the options are fully vested and exercisable on June 14, 2027, subject to acceleration upon a change in control pursuant to the terms of the Option Agreement ("CIC") by and between the Reporting Person and the Issuer and continued service by the Reporting Person. In addition, following a CIC, the exercise period of the option shall be extended to 12 months following termination of service, other than in the event of termination For Cause (as defined in the Plan). These options vest and become exercisable pursuant to the following schedule: 25% of the options shall vest on November 8, 2023, and the remainder shall vest over three years in quarterly equal installments, subject to acceleration upon a change in control ("CIC") and continued service by the Reporting Person. In addition, following a CIC, the exercise period of the option shall be extended to 12 months following termination of service, other than in the event of termination For Cause (as defined in the Plan). These options vest and become exercisable pursuant to the following schedule: 25% of the options vested on November 11, 2022, and the remainder shall vest over three years in quarterly equal installments, subject to acceleration upon a change in control pursuant ("CIC") and continued service by the Reporting Person. In addition, following a CIC, the exercise period of the option shall be extended to 12 months following termination of service, other than in the event of termination For Cause (as defined in the Plan). /s/ David S. Glatt, Attorney-in-Fact for Sigal Fatal 2023-06-16